Abstract
Botulinum toxin (BT) is used in urology and neurourology since the end of the 80s. Its ease of use and some promising results incite to try it in numerous indications. Treatment of neurogenic detrusor hyperactivity with BT is considered valid. There are clinical studies of high level of evidence for treatment of idiopathic overactive bladder symptoms and detrusor-spincter dyssynergia, but it is not considered valid yet, because inclusion criteria and adverse effects are not perfectly estimated. Evaluations of other indications (benign prostatic hyperplasia for example) are there still at their beginning. Two molecules are marketed in France, without comparison studies. Clinical studies are still mandatory in order to clarify posology, modality of injection and therapeutic strategy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
